43．Treatment pattern and outcomes of trifluridine/tipiracil therapy for metastatic colorectal cancer in the real-world data from the JFMC50 study
T. Kawakami, K. Yamazaki, E. Oki, M. Shimokawa, N. Takahashi, M. Yokota, S. Tokunaga, T. Esaki, M. Gamoh, A. Maeda, Y. Tsuji, A. Sakai, K. Hatanaka, Y. Shimada, M. Shiozawa, Y. Komatsu, H. Okuda, M. Ohue, Y. Maehara, et al.
[JFMC50-1701-C6]
■ Society of Surgical Oncology 2018 2018/3 Chicago
42．Daikenchuto for Postoperative Bowel Dysfunction After Open Abdominal Surgery: A Pooled Analysis of Three Randomized Controlled Trials.
Nishi M, Shimada M, Kono T, et al.
[JFMC39-0902 ,JFMC40-1001 , JFMC42-1002]
■ ASCO-GI 2018 2018/1 San Francisco
41．Age, gender, and performance status effects on efficacy of 3 versus 6 months of adjuvant oxaliplatin and fluoropyrimidine chemotherapy for stage III colon cancer: Phase III ACHIEVE trial as part of the IDEA collaboration
Kato T , Yoshino T , Yamanaka T , et al.
[JFMC47-1202-C3]
40．Efficacy of daikenchuto for the intestinal hypomotility after open abdominal surgery: A pooled analysis of three randomized controlled trials.
Kono T, Shimada M, Nishi M, et al.
[JFMC39-0902 ,JFMC40-1001 , JFMC42-1002]
2017年
■ ESMO Asia 2017 2017/11 Singapore
39．Impact of postoperative complications on the colorectal cancer survival and recurrence:
Analyses of pooled individual patients’ data from three large phase III randomized trials
Aoyama T, Oba K , Honda M, et al.
[JFMC7-8601,JFMC15-8901,JFMC33-0502]
■ ESMO 2017 2017/9 Madrid
38．Effect of lateral lymph node dissection for lower rectal cancer: An ad hoc analysis of the ACTS-RC randomized clinical trial．
Oki E, Shimokawa M, Murata A, et al.
[JFMC35-C1(ACTS-RC)]
37．Safety and efficacy of S-1 treatment in elderly patients with advanced or recurrent gastric cancer: a subgroup analysis from the phase III JFMC36-0701 trial．
Nishikawa K, Yoshino S, Morita S, et al.
[JFMC36-0701]
36．Efficacy of 3 versus 6 months of oxaliplatin-based adjuvant chemotherapy for Stage III colon cancer (CC): Results from phase III ACHIEVE trial as part of the International Duration Evaluation of Adjuvant therapy (IDEA) Collaboration．
Yoshino T, Yamanaka T, Kotaka M, et al.
[JFMC47-1202-C3]
■ ASCO-GI 2017 2017/1 San Francisco
35．Baseline Creatinine Clearance as an Indicator of Severe Adverse Events Associated with Oxaliplatin-based Adjuvant Chemotherapy in Patients with Stage III Colon Cancer: Safety Analysis of the Phase III Japanese ACHIEVE trial．
Nakamura M, Kotaka M, Eto T, et al.
[JFMC47-1202-C3]
34．Treatment Outcome and Recovery from Peripheral Sensory Neuropathy during a 3-Year Follow-Up in Patients Receiving Modified FOLFOX6 as Adjuvant Treatment for Stage II/III Colon Cancer (JFMC41-1001-C2: JOIN Trial)．
Manaka D, Kotaka M, Shinozaki K, et al.
[JFMC41-1001-C2]
2016年
33．ESMO2016 2016/10 Copenhagen
Phase III Trial of 24 Weeks vs. 48 Weeks CapecitabineAdjuvant Chemotherapy for Patients with Stage III Colon Cancer: Final Results of JFMC37-0801.
Yamaguchi S, Kunieda K, Sato T, et al.
[JFMC37-0801]
32．ESMO-GI/WCGC2016 2016/6 Barcelona
An international phase III randomized, non-inferiority trial comparing 3 vs 6 months of oxaliplatin-based adjuvant chemotherapy for colon cancer: compliance and safety of the phase III Japanese ACHIEVE trial.
Eto T, Kotaka M, Manaka D, et al.
[JFMC47-1202-C3]
31．ASCO2016 2016/6 Chicago
An international phase III randomized, non-inferiority trial comparing 3 vs 6 months of oxaliplatin-based adjuvant chemotherapy for colon cancer: compliance and safety of the phase III Japanese ACHIEVE trial.
Eto T, Kotaka M, Manaka D, et al.
[JFMC47-1202-C3]
2015年
30．ECCO 18 – ESMO 40 2015/9 Vienna
A randomized phase III study of S-1 alone versus S-1 plus immunomodulator lentinan for unresectable or recurrent gastric cancer (JFMC36-0701).
Nishikawa K, Yoshino S, Morita S, et al.
[JFMC36-0701]
29．ASCO2015 2015/6 Chicago
A randomized phase III trial comparing S-1 versus UFT as adjuvant chemotherapy for stage II/III rectal cancer.(JFMC35-C1:ACTS-RC)
Murata A, Yoshida K, Maeda K, et al.
[JFMC35-C1(ACTS-RC)]
2014年
28．2014ASCO 2014/6 Chicago
Two phase III studies comparing 6 months of either mFOLFOX6 or XELOX with 3 months of the same regimen as adjuvant chemotherapy in patients with completely resected stage III colon cancer (ACHIEVE) or high-risk stage II colon cancer (ACHIEVE-2)．
Yoshino T, Watanabe T, Mori M, et al.
[JFMC47-1202-C3/JFMC48-1301-C4]
27．DDW2014 2014/5 Chicago
Daikenchuto (DKT) helps improve postoperative functional gastrointestinal disorder after total gastrectomy in patients with gastric cancer: A multicenter, randomized, double-blind, placebo-controlled trial (JFMC42-1002)．
Koeda K, Wakabayashi G, Shimada M, et al.
[JFMC42-1002]
■ 2014ASCO-GI 2014/1 San Francisco
26．Tolerability study of adjuvant modified FOLFOX6 treatment in curatively resected stage II/III colon cancer (JFMC41-1001-C2: JOIN Trial)．
Shinozaki K, Kotaka M, Touyama T, et al.
[JFMC41-1001-C2]
25．Efficacy and safety result of trastuzumab (T-mab) and Paclitaxel for T-mab naive patients with HER2 positive previously treated advanced or recurrent gastric cancer (JFMC45-1102): Final report．
Takahashi T, Nishikawa K, Miki A, et al.
[JFMC45-1102]
2013年
24．2013ECCO(ESMO) 2013/9 Amsterdam
Phase III trial of treatment duration for oral Uracil and Tegafur/Leucovorin adjuvant chemotherapy for patients (pts) with stage IIB/III colon cancer : Final results of JFMC33-0502．
Sadahiro S, Tsuchiya T, Sasaki K, et al.
[JFMC33-0502]
■ ESCP2013 2013/9 Beograd
23．Clinical pharmacology of daikenchuto for colon cancer patients having colectomy: transit analysis of a randomized, double-blind, multicenter, placebo-controlled trial (JFMC39-0902 Additional study)．
Yoshimitsu M, Maeda K, Kouda K, et al.
[JFMC39-0902付随]
22．Clinical efficacy of daikenchuto for colon cancer patients having colectomy: 1-year follow-up of a randomized, double-blind, multicenter, placebo-controlled trial (JFMC39-0902)．
Matsuhashi N, Maeda K, Kunieda K, et al.
[JFMC39-0902]
21．IGCC2013 2013/6 Verona
Significance of fluorescence in-situ hybridization in metastatic gastric cancer with HER2 immunohistochemistry 0 or 1+ : Prospective cohort study, JFMC44-1101．
Tsuburaya A, Chin K, Nashimoto A, et.al.
[JFMC44-1101]
■ 2013ASCO 2013/6 Chicago
20．Multicenter, phase II study of trastuzumab and paclitaxel to treat HER2-positive, metastatic gastric cancer patients naïve to trastuzumab (JFMC45-1102)．
Iwasa S, Nishikawa K, Miki A, et al.
[JFMC45-1102]
19．Tumor and stromal autophagy is related to endocrine responsiveness in breast cancer tissues．
Ueno T, Masuda N, Saji S, et al.
[JFMC34-0601付随]
■ 2013ASCO-GI 2013/1 San Francisco
18．Result of HER2 status in Japanese metastatic gastric cancer -Prospective cohort study (JFMC44-1101)．
Nishikawa K, Chin K, Nashimoto A, et al.
[JFMC44-1101]
17．Efficacy and safety of trastuzumab and paclitaxel for trastuzumab naïve patients with HER2 positive previously treated metastatic gastric cancer (JFMC45-1102)．
Miki A, Nishikawa K, Noshiro H, et al.
[JFMC45-1102]
2012年
16．35th SABC 2012/12 San Antonio
Increase of serum androgen and its metabolites in postmenopausal primary breast cancer patients with disease progression during neo-adjuvant exemestane treatment; JFMC 34-0601 TR.
Takada M, Saji S, Honma N, et al.
[JFMC34-0601付随]
15．2012年米国肝臓学会議（AASLD2012） 2012/11 Boston
Daikenchuto improves functional gastrointestinal disorder after hepatic resection in patients with primary or metastatic liver cancer: a multicenter, randomized, double-blind, placebo-controlled phase Ⅱ trial (JFMC40-1001).
Hatano E, Kobayashi S, Kaiho T, et al.
[JFMC40-1001]
■ 37th ESMO 2012/9 Vienna
14．PHASE Ⅲ TRIAL OF TREATMENT DURATION FOR ORAL URACIL AND TEGAFUR/LEUCOVORIN ADJUVANT CHEMOTHERAPY FOR PATIENTS (PTS) WITH STAGE ⅡB/Ⅲ COLON CANCER: RESULTS OF JFMC33-0502.
Kondo K, Sadahiro S, Tsuchiya T, et al.
[JFMC33-0502]
13．Serum concentration of Estrone (E1), not Estradiol (E2), is the independent predictive factor of response to neo-adjuvant exemestane treatment in postmenopausal breast cancer patients: JFMC 34-0601 TR.
Saji S, Takada M, Honma N, et al.
[JFMC 34-0601付随]
12．HRQOL DURING ADJUVANT CHEMOTHERAPY WITHCAPECITABINE IN PATIENTS AFTER SURGERY FOR COLON CANCER:ADDITIONAL STUDY OF JFMC37-0801.
Kinugasa Y, Shiroiwa T, Nakamura M, et al.
[JFMC37-0801付随]
HRQOL during Adjuvant Chemotherapy with Capecitabine in patients after surgery for Colon Cancer：Additional Study of JFMC37-0801.
Ishiguro M, Shiroiwa T, Fukuda T, et al.
[JFMC37-0801付随研究]
10．2012ASCO 2012/6 Chicago
Six months versus twelve months of Capecitabine as Adjuvant Chemotherapy for Stage III (Dukes’C) Colon Cancer – Initial safety report for the open-label randomized phase III study (JFMC37-0801).
Kunieda K, Sadahiro S, Mishima H, et al.
[JFMC37-0801]
2011年
９．36th ESMO 2011/9 Stockholm
PHASE Ⅲ TRIAL OF TREATMENT DURATION OF ORAL URACIL AND TEGAFUR/LEUCOVORIN ADJUVANT CHEMOTHERAPY FOR PATIENTS(PTS) WITH STAGE ⅡB/Ⅲ COLON CANCER: AN INTERIM SAFETY AND FEASIBILITY REPORT,JFMC33-0502.
Sasaki K, Sadahiro S, Tsuchiya T, et al.
[JFMC33-0502]
８．2011ASCO 2011/6 Chicago
A study of the recurrence score by the 21-gene signature assay as a predictor of clinical response to neoadjuvant exemestane for 24 weeks in estrogen-receptor positive breast cancer.
Masuda N, Toi M, Ueno T, et al.
[JFMC34-0601]
７．2011ASCO-GI 2011/1 San Francisco
6 months versus 12 months of Capecitabine as Adjubant Chemotherapy for StageⅢ (Dukes’C) Colon Cancer: Rationale for the open-label randomized phaseⅢｓtudy (JFMC37-0801).
Takahashi T, Yoshida K, Hamada C, et al.
[JFMC37-0801]
2010年
６．第20回広島がんセミナー・第4回三大学コンソーシアム共催国際シンポジウム 2010/10 広島
PHASEⅡSTUDY OF NEOADJUVANT EXEMESTANE FOR 24 WEEKS IN POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE BREAST CANCER：(JFMC34-0601).
Saji S.
[JFMC34-0601]
５．6th Annual Conference of Organisation for Oncology and Translational Research 2010/2 Kyoto
Increased estrogen sulfatase (STS) and 17β- hydroxysteroid dehydrogenase type 1(17β-HSD1) after neoadjuvant aromatase inhibitor therapy in breast cancer patients.
Chanplakorn N, Chanplakorn P, Ono K, et al.
[JFMC34-0601 ]
2009年
４．2009ASCO 2009/05 Orlando
Neoadjuvant Exemestane for 24 weeks in postmenopausal women with hormone receptor positive Stage II or IIIA breast cancer: (JFMC34-0601).
Sato N, Masuda N, Saji S, et al.
[JFMC34-0601]
2008年
３．33rd ESMO 2008/09 Stockholm
RANDOMIZED PHASE Ⅱ CLINICAL TRIAL OF TAILORED IRINOTECAN(CPT-11) PLUS S-1 VERSUS S-1 IN PATIENTS WITH ADVANCED OR RECURRENT GASTRIC CARCINOMA AS THE FIRST-LINE CHEMOTHERAPY (THE JAPANESE FOUNDATION FOR MULTIDISCIPLANARY TREATMENT OF CANCER, JFMC31-0301).
Takahashi Y, Komatsu Y, Kitajima M, et al.
[JFMC31-0301]
2005年
２．6thIGCA 2005/5 Yokohama
Is Favorable Survival Related to Adverse Effects during S-1 + Low Dose Cisplatin Regimen
（JFMC27-9902)
for Gastric Cancer?
Nakata B.
[JFMC27-9902]
2004年
１．2004ASCO 2004/6 New Orleans
Combination therapy of a novel oral fluorouracil derivative S-1 with low-dose cisplatin for unresectable and recurrent gastric cancer: JFMC27-9902 phase I trial.
Nakata B, Tsuji A, Mitachi Y, et al.
[JFMC27-9902]
Ⅱ.国内学会
2018年
■ 第56回日本癌治療学会 2018/10 横浜
64．Treatment pattern and outcomes of trifluridine/tipiracil therapy for metastatic colorectal cancer in the real-world data from the JFMC50 study
T. Kawakami, K. Yamazaki, E. Oki, M. Shimokawa, N. Takahashi, M. Yokota, S. Tokunaga, T. Esaki, M. Gamoh, A. Maeda, Y. Tsuji, A. Sakai, K. Hatanaka, Y. Shimada, M. Shiozawa, Y. Komatsu, H. Okuda, M. Ohue, Y. Maehara, et al.
[JFMC50-1701-C6]
62．Efficacy results on Stage III colon cancer with oxaliplatin-based adjuvant chemotherapy for 3 versus 6 months: Results from the phase III Japanese ACHIEVE (JFMC47) Trial
Yoshino T, Yamanaka T, Kotaka M, et al.
[JFMC47-1202-C3]
60．Treatment outcome and recovery from peripheral sensory neuropathy during a 3-year follow up in patients receiving adjuvant modified FOLFOX6 for Stage II/III Colon Cancer（JFMC41-1001-C2：JOIN Trial）
松井隆則，小髙雅人，篠崎勝則，他
[JFMC41-1001-C2]
59．Baseline creatinine clearance as an indicator of severe adverse events associated with oxaliplatin-based adjuvant chemotherapy for Stage III Colon Cancer：Safety analysis in phase III ACHIEVE trial
高金明典，小髙雅人，江頭徹哉，他
[JFMC47-1202-C3]
Randomised phase III study of S-1 alone versus S-1 plus lentinan for unresectable or recurrent gastric cancer (JFMC36-0701).
吉野茂文，西川和宏，森田智視，他
〔JFMC36-0701〕
■ 第14回日本臨床腫瘍学会学術集会 2016/7 神戸
56．Compliance and Safety Analysis of ACHIEVE trial: the Japanese Phase III Randomized Trial of International IDEA Project (JFMC47).
間中 大, 小高 雅人, 江頭 徹哉, 他
[JFMC47-1202-C3]
55．Large-Scale Prospective Pharmacogenomics Study of Oxaliplatin lnduced Neuropathy in Colon Cancer Patients.
金井 雅史, 川口 喬久, 松本 繁巳, 他
[JFMC41-1001-C2付随]
49．本邦の切除不能進行・再発胃癌におけるHER2 status の検討 -前向き観察研究 （JFMC44-1101）
富田寿彦，陳勁松，梨本篤，他
[JFMC44-1101]
48．Tolerability study of adjuvant modified FOLFOX6 in curatively resected stage II/III colon cancer (JFMC41-1001-C2:JOIN Trial)．
當山鉄男，小髙雅人，篠崎勝則，他
[JFMC41-1001-C2]
47．シンポジウム「データマネージメントの現状と今後」；大規模臨床試験におけるEDC(Electronic Data Capture)の活用と問題点
内形洋志